GSK 2816126

Drug Profile

GSK 2816126

Alternative Names: GSK-2816126

Latest Information Update: 11 Feb 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics
  • Mechanism of Action EZH2 enzyme inhibitors; Histone modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diffuse large B cell lymphoma; Follicular lymphoma
  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 08 Feb 2017 Phase-I clinical trials in Diffuse large B cell lymphoma (Second-line therapy or greater) in France (IV) before February 2017 (NCT02082977)
  • 08 Feb 2017 Phase-I clinical trials in Follicular lymphoma (Second-line therapy or greater) in France (IV) before February 2017 (NCT02082977)
  • 03 Dec 2016 Efficacy, adverse events and pharmacokinetic data from a phase I trial in Diffuse large B cell lymphoma and Follicular lymphoma (Second line therapy or greater) presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top